News headlines about Aduro BioTech (NASDAQ:ADRO) have trended somewhat positive on Tuesday, Accern reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aduro BioTech earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.1021300584863 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern’s scoring:
- -$0.36 EPS Expected for Aduro BioTech Inc (ADRO) This Quarter (americanbankingnews.com)
- Aduro BioTech (ADRO) Cut to “Strong Sell” at BidaskClub (americanbankingnews.com)
- Aduro BioTech, Inc. (ADRO) stock is worth at $6.70 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Is technical analysis on Aduro BioTech, Inc. (ADRO) is useful? – Wall Street Morning (wallstreetmorning.com)
- Aduro BioTech Inc (ADRO) Given Average Recommendation of “Buy” by Brokerages (americanbankingnews.com)
ADRO has been the topic of a number of research reports. BidaskClub lowered shares of Aduro BioTech from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. ValuEngine lowered shares of Aduro BioTech from a “sell” rating to a “strong sell” rating in a research report on Friday. HC Wainwright set a $10.00 target price on shares of Aduro BioTech and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Canaccord Genuity set a $30.00 target price on shares of Aduro BioTech and gave the stock a “buy” rating in a research report on Thursday, December 14th. Finally, Oppenheimer set a $15.00 price target on shares of Aduro BioTech and gave the stock a “buy” rating in a research note on Monday, December 11th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Aduro BioTech has an average rating of “Buy” and a consensus target price of $17.71.
In related news, EVP Dirk G. Brockstedt sold 65,223 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $8.11, for a total transaction of $528,958.53. Following the completion of the sale, the executive vice president now directly owns 137,826 shares of the company’s stock, valued at $1,117,768.86. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Stephen T. Isaacs sold 19,800 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $7.97, for a total transaction of $157,806.00. Following the sale, the insider now directly owns 190,321 shares of the company’s stock, valued at $1,516,858.37. The disclosure for this sale can be found here. Over the last three months, insiders have sold 223,391 shares of company stock valued at $1,897,707. 6.60% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: This article was posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.com-unik.info/2018/02/06/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-aduro-biotech-adro-stock-price.html.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.